Barclays raised the firm’s price target on Syneos Health to $45 from $30 and keeps an Underweight rating on the shares after Reuters reported that the company is putting itself up for sale. The analyst’s sum-of-the-parts analysis shows "significant potential upside" to current shares from the business breaking up. However, the firm has limited confidence in Syneos Health’s fundamentals in 2023 and 2024.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SYNH:
- Syneos Health launches Decentralized Clinical Trial Site Network
- Syneos Health Unveils New Decentralized Clinical Trial Site Network to Drive DCT Adoption
- Baird sees more value in Syneos than market, but says buyer would ‘need resolve’
- Syneos Health jumps following report on new effort to sell itself
- Syneos Health hires Bank of America to help seek buyer, Reuters says